Limited Submission Deadline: NIH Asthma and Allergic Diseases Cooperative Research Centers

Limited Submissions: Internal Call for Proposals 
National Institute of Health

Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)

UNC Internal deadline: 11:59PM, Friday, May 15, 2020

 

*Please distribute to relevant faculty*

Key Dates

UNC Internal Deadline: 11:59PM, Friday, May 15, 2020

NIH LOI Deadline: July 28, 2020

NIH Application Deadline: August 28, 2020

Important Information

• Number of Applications per Institution: Organizations may only submit one nomination.

Award Information

Award Budget: $900,000 in direct costs per year, excluding the IOF budget, and need to reflect the actual needs of the proposed project.

Award Project Period: The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Cost Sharing: Not required.

To Apply

Submit the following (in ONE .pdf)  to the Office of Research Development limited submissions inbox Limited_Submissions@unc.edu by 11:59PM, Friday, May 15, 2020.

1. PI/Proposed team member’s CV/NIH formatted biosketch (five-page maximum)
2. Project Summary (no more than 4 pages)
3. List of potential/committed collaborators (internal and external to UNC)
4. Names of 3-5 internal (to UNC) experts who could speak knowledgeably about the candidate’s research and who could potentially serve on an internal review panel.
   • Please do not include the names of faculty named on the project, chairs, deans, directors, direct reports, or others who have a conflict of interest. 
   • Please notify all potential internal reviewers before submitting the pre-proposal packet to ORD.

Program Overview

Background: Asthma and allergic diseases are major causes of illness and disability in the United States and the prevalence of these conditions is still on the rise. Also of high prevalence and morbidity are chronic rhinosinusitis and non-allergic rhinitis, which share pathophysiologic and clinical characteristics with allergic diseases. In all these conditions, major gaps exist in our understanding of their immunopathophysiology and, for most of them, management is either based on avoidance of allergens or pharmacologic interventions that offer either only symptomatic relief or have nonspecific anti-inflammatory activities that do not alter the natural history of the disease. Allergen immunotherapy for food and aeroallergens or early dietary introduction of food allergens offer promise in disease modification and prevention but require further study.

This Funding Opportunity Announcement (FOA) invites applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.

 

The objective of this FOA is to support multidisciplinary research on the following conditions of interest: immunopathophysiology of asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overall goal of the AADCRC program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.

NIAID programmatic priorities for this FOA are:

• The role of innate and adaptive immune functions in the development and pathogenesis of asthma and allergic diseases with a focus on severe asthma, chronic rhinosinusitis, atopic dermatitis, and drug allergy;
• The impact of the microbiome and pollution on immune responses as they pertain to the development, prevention and management of asthma, allergic rhinitis, food allergy and atopic dermatitis;
• The interaction between infections and atopy and the role of immune responses to infections in the development and exacerbations of asthma, allergic rhinitis, chronic rhinosinusitis, and atopic dermatitis;
• Induction of and understanding of the mechanisms of desensitization and sustained tolerance for the treatment and prevention of asthma, allergic rhinitis, food allergy, and drug allergy;
• Genetic variations and epigenetic alterations affecting host immune responses to aeroallergens, food allergens and drug allergens and host response to therapeutic interventions;
• Clinical, immunologic and physiologic phenotyping and endotyping of drug allergy, atopic dermatitis, chronic rhinosinusitis and non-allergic rhinitis syndromes that provide mechanistic insights for disease etiology or management.

 

Program Restrictions

Applications including the following studies will be considered non-responsive and will not be reviewed:

1. • Research on autoimmunity and autoimmune diseases;
   • Research on primary immune deficiency diseases;
   • Demonstration and Education Research Projects;
   • Phase III clinical trials;
   • Clinical trials at foreign sites;
   • Continuation of ongoing (active) clinical trials. The applicant may only propose new clinical trials.  For the purpose of this FOA, a new trial is defined as one that has not previously recruited any subjects and will not be recruiting any subjects prior to award;
   • Applications in which human research is not the focus;
   • Research on HIV or AIDS.

 

In order to ensure the focus of the applications is on human disease, the proposed research within each application should be defined as human subjects research (for the HHS definition of human subjects research, please see the NIH Office of Extramural Research Human Subjects) or utilize human material (including primary human cells, biologic samples, and clinical data). Studies using only transformed human cell lines will not count toward this requirement. Very limited animal research may be included based on the need for experimentation that is not possible in humans or with human materials and the animal studies must be clearly integrated into an overall experimental plan that will translate animal findings to human disease.

 

Additional Information

Full Solicitation: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-007.html

 

For additional information, please contact the Limited Submissions Team with questions at Limited_Submissions@unc.edu.

 

 

 

Limited Submissions Team

Office of Research Development

University of North Carolina at Chapel Hill

308 Bynum Hall

Chapel Hill, NC 27599

(919) 962-7503